Microsoft creator Bill Gates' charity foundation has devoted a huge amount to fund further the research for HIV-preventing drug implants and other cause that can prevent HIV outbreak. The Bill and Melinda Gates Foundation is funding up to $140 million for the groundbreaking new tech, which could revolutionize HIV prevention.
Now, prevention drugs are accessible as a pill that, if taken daily, can immensely reduce a person's chances of being infected with HIV. The drugs are approved by the World Health Organisation for use by at-risk groups together with men who have sex with men carries the virus - but are only the current pills are taken consistently.
Bill & Melinda Gates Foundation Funded The Research To Attain Maximum Tolerance On HIV
There are optimists that implant technology, like systems available for birth control, could be hand-down to deliver a reliable supply of drugs, aiding people susceptible to the virus.
Ahead of large-scale trials of PrEP implants, the Bill and Melinda Gates Foundation has come in a relationship with pharma company Intarcia Therapeutics to study and create the tech. It has promised $50 million towards the initial development, with a further $90 million subsidy tied to milestone goals, and an obligation to further development grants if fruitful. A Total of $140 Million to be endorsed on the research team.
Sue Desmond-Hellmann, CEO of the Bill & Melinda Gates Foundation, said: "There's a vigorous need for an HIV/AIDS involvement that allows those at risk to integrate prevention more straightforwardly into their daily lives. "We feel encouraging about our partnership with Intarcia and the dream of an implantable prophylactic device that could make a world of change for people most in need."
Kurt Graves, Chairman, President, and CEO of Intarcia Therapeutics said: "We are extremely excited and humbled to work with an incredible association as smart, forward-looking and purpose-based as the Bill & Melinda Gates Foundation."
The company enlightens: "A matchstick-sized osmotic mini-pump that is positioned just under the dermal layer of skin to deliver a nonstop and consistent flow of medicine.
"Once a drug is legalized, a trained healthcare specialist can place the small device in an in-office practice. Each osmotic mini-pump is intended to hold a suitable volume of drug to treat a patient for up to a full year."
